Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 491 - Bridging Causal Inference and Clinical Trials
Type: Invited
Date/Time: Thursday, August 11, 2022 : 8:30 AM to 10:20 AM
Sponsor: Society for Clinical Trials
Abstract #319281
Title: Sensitivity of Causal Estimands in Clinical Trials with Imperfect Compliance
Author(s): Heng Chen* and Daniel F. Heitjan
Companies: Gilead Sciences, Inc. and Southern Methodist University
Keywords: Complier average causal effect; Intention-to-treat; Noncompliance; Randomization; Sensitivity
Abstract:

In clinical trials that are subject to noncompliance we commonly seek to estimate the intention-to-treat (ITT) estimand, which does not measure the causal effect of the treatment received and is sensitive to the level of compliance. An alternative estimand, the complier average causal effect (CACE), refers to the average effect of treatment received in the latent subset of subjects who would comply with either treatment. Under the Rubin Causal Model (RCM), five assumptions are sufficient to identify CACE and enable its consistent estimation from trial data. Taking compliance itself to be a random quantity, we observe that CACE can also vary with the fraction of compliance. We propose a “sixth assumption” that specifies that, at the subject level, the randomized treatment effect on compliance is independent of the total causal effects of both randomized treatment and treatment actually received on outcome, in the superpopulation from which trial samples are drawn. This assumption guarantees robustness of CACE to the compliance fraction. We demonstrate the potential degree of sensitivity in a simulation study and a data analysis from a trial of vitamin A supplementation in children.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program